Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022
October 18 2022 - 9:00AM
Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage
CRISPR genome-editing biopharmaceutical company, today announced
the presentation of a case report for long-term follow up on the
first patient dosed in its ANTLER Phase 1 clinical trial for CB-010
in relapsed or refractory aggressive B cell non-Hodgkin lymphoma
(r/r B-NHL). A recent evaluation showed the patient has maintained
a complete response (CR) at 15 months after a single dose of
CB-010. The case report will be presented at the Lymphoma,
Leukemia, & Myeloma Congress being held in New York City, New
York on October 18-22, 2022.
The poster presentation provides long-term data for the first
patient treated in the ANTLER Phase 1 clinical trial with a single
dose of CB-010 administered at dose level 1 (40x106 CAR-T cells).
The patient is a 66-year-old male, diagnosed in 2013 with
aggressively behaving follicular lymphoma (FL), demonstrating
progression of disease within 24 months (POD24). Before joining the
ANTLER trial, the patient had received eight prior lines of
systemic anti-cancer therapy. After a single dose of CB-010, the
patient initially demonstrated a CR at 28 days, which has been
maintained through his 15-month evaluation.
“The 15-month CR for the first patient in the ANTLER trial
exceeded our expectations at this initial dose level and we are
highly encouraged by this outcome as we aim to set a new
therapeutic bar for patients with relapsed or refractory
B-NHL,” said Rachel Haurwitz, Ph.D., Caribou’s president and chief
executive officer. “There is a significant unmet need for an
allogeneic cell therapy that can rival the efficacy of autologous
cell therapies. We believe that the safety and efficacy profile of
CB-010 at dose level 1 has laid the foundation for the promise of
this off-the-shelf cell therapy to meet that patient need. As we
continue enrollment in the ANTLER trial, our goal is to build upon
this foundation by assessing CB-010’s safety and durability at a
higher dose level.”
CB-010 is the first allogeneic anti-CD19 CAR-T cell therapy in
the clinic with a PD-1 knockout, a genome-editing strategy designed
to improve the persistence of antitumor activity by limiting
premature CAR-T cell exhaustion.
Based on the promising initial safety data and response rate at
dose level 1, the ANTLER trial is enrolling patients at dose level
2 (80x106 CAR-T cells). Caribou plans to share additional ANTLER
data from cohort 1 by the end of 2022.
Details of the poster presentation at the Lymphoma, Leukemia,
& Myeloma Congress 2022 are as follows:
Title: A CRISPR-edited Allogeneic Anti-CD19
CAR-T Cell Therapy with PD-1 Knockout Induces Prolonged Complete
Response in Relapsed/Refractory Follicular Lymphoma Patient: Case
Report from CB-010 ANTLER StudyAbstract: 1328080
(P-004)Presenter: John L. Harcha, M.D., M.H.A.,
Chief Internal Medicine Resident, Jewish Hospital-Mercy Health in
affiliation with Oncology Hematology Care, Cincinnati,
OHAvailable on LL&M e-poster platform:
Tuesday, October 18, 2022, at 9:00 am ETLymphoma
Categories: Clinical Case Report
(L4)Location: Sheraton New York Times Square
Hotel
The poster is available on the Scientific Publications page of
the Technology section of Caribou’s website.
About CB-010CB-010 is the lead product
candidate from Caribou’s allogeneic CAR-T cell therapy platform and
is being evaluated in patients with relapsed or refractory B cell
non-Hodgkin lymphoma (r/r B-NHL) in the ongoing ANTLER Phase 1
trial. CB-010 is an allogeneic anti-CD19 CAR-T cell therapy
engineered using Cas9 CRISPR hybrid RNA-DNA (chRDNA) technology to
insert a CD19-specific CAR into the TRAC gene and knock out PD-1 to
boost the persistence of antitumor activity. CB-010 is the first
allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout.
Additional information on the ANTLER trial can be found at
https://clinicaltrials.gov using identifier NCT04637763.
About Caribou’s Novel Next-Generation CRISPR
Platform CRISPR genome editing uses easily designed,
modular biological tools to make DNA changes in living cells. There
are two basic components of Class 2 CRISPR systems: the nuclease
protein that cuts DNA and the RNA molecule(s) that guide the
nuclease to generate a site-specific, double-stranded break,
leading to an edit at the targeted genomic site. CRISPR systems are
capable of editing unintended genomic sites, known as off-target
editing, which may lead to harmful effects on cellular function and
phenotype. In response to this challenge, Caribou has developed
CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”)
that direct substantially more precise genome editing compared to
all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA
technology to carry out high efficiency multiple edits, including
multiplex gene insertions, to develop CRISPR-edited
therapies.
About Caribou Biosciences,
Inc.Caribou Biosciences is a clinical-stage CRISPR
genome-editing biopharmaceutical company dedicated to developing
transformative therapies for patients with devastating diseases.
The company’s genome-editing platform, including its proprietary
Cas12a chRDNA technology, enables superior precision to develop
cell therapies that are specifically engineered for enhanced
persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T
and CAR-NK cell therapies for the treatment of patients with
hematologic malignancies and solid tumors.
Follow us @CaribouBio and visit www.cariboubio.com.
“Caribou Biosciences” and the Caribou logo are registered
trademarks of Caribou Biosciences, Inc.
Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, without limitation,
statements related to Caribou’s strategy, plans, and objectives,
and expectations regarding its clinical and preclinical development
programs, including its expectations relating to the timing of the
release of additional patient data from its ANTLER Phase 1 clinical
trial for CB-010. Management believes that these forward-looking
statements are reasonable as and when made. However, such
forward-looking statements are subject to risks and uncertainties,
and actual results may differ materially from any future results
expressed or implied by the forward-looking statements. Risks and
uncertainties include, without limitation, risks inherent in the
development of cell therapy products; uncertainties related to the
initiation, cost, timing, progress, and results of Caribou’s
current and future research and development programs, preclinical
studies, and clinical trials; and the risk that initial or interim
clinical trial data will not ultimately be predictive of the safety
and efficacy of Caribou’s product candidates or that clinical
outcomes may differ as more patient data becomes available; as well
as other risk factors described from time to time in Caribou’s
filings with the Securities and Exchange Commission, including its
Annual Report on Form 10-K for the year ended December 31, 2021,
and subsequent filings. In light of the significant uncertainties
in these forward-looking statements, you should not rely upon
forward-looking statements as predictions of future events. Except
as required by law, Caribou undertakes no obligation to update
publicly any forward-looking statements for any reason.
Caribou Biosciences, Inc.
Contacts: |
InvestorsAmy
Figueroa, CFA |
afigueroa@cariboubio.comMediaPeggy Vorwald,
Ph.D.pvorwald@cariboubio.com |
|
Investors and
Media: |
Elizabeth Wolffe, Ph.D., and
Sylvia Wheeler |
Wheelhouse LSA |
lwolffe@wheelhouselsa.com |
swheeler@wheelhouselsa.com |
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Caribou Biosciences (NASDAQ:CRBU)
Historical Stock Chart
From Jul 2023 to Jul 2024